Jul 31 2016
Stealthy Auris Health, Inc., formerly known as Auris Surgical Robotics, made the list of 10 robotic surgery companies to be watched. According to the article, robotic technology may be a less invasive approach with higher success rates, in comparison to today’s more traditional approaches. Auris was specifically mentioned for its impressive funding and 2016 FDA clearance for its robotic endoscopy system, ARES (Auris Robotic Endoscopy System).Continue Reading
Jul 28 2016
Silicon Valley-based Auris Health, made headlines for the FDA clearance of its robotic endoscopy system ARES (Auris Robotic Endoscopy System). According to the article, the technology could assist physicians with both visualizing and treating several lung conditions. Auris’s advanced bronchoscopic system could also make the procedure easier to perform for physicians, according to the article. Auris’s robotic approach could allow for less fatigue on the medical professional, unlike traditional bronchoscopy procedures.Continue Reading
Jun 07 2016
Auris Health, Inc., formerly known as Auris Surgical Robotics, is featured in this article for its FDA-cleared ARES, Auris Robotic Endoscopy System, and the curiosity it brings to what the company could plan to do with its technology.Continue Reading
Apr 20 2016
Auris Health, Inc, formerly known as Auris Surgical Robotics, was excited not only for its purchase of minimally invasive robotic surgery company Hansen Medical, but also for the opportunity the acquisition would bring Auris. According to the article, the acquisition could put Auris in a position to capitalize on robotic surgery and transcatheter, minimally invasive surgical procedures.Continue Reading
Apr 20 2016
Auris’s $80 million acquisition of robotics company Hansen Medical, founded by Dr. Fred Moll, made headlines. According to the article, Dr. Moll, a serial entrepreneur and robotics innovator, is excited about the business deal and what opportunities lie ahead.Continue Reading
Sep 25 2015
Auris is being watched by the tech community, especially as healthcare tech funding gains popularity, according to this article. There has been an increase in funding for the sector, and Auris is mentioned as one of the companies innovating the space.Continue Reading
Sep 24 2015
Auris Health, Inc, formerly known as Auris Surgical Robotics, was featured for its impressive $150 million Series B funding. The article also mentioned Auris’s previous financial partners, which include Peter Theil's Mithril Capital, and its total financing to date.Continue Reading
Apr 29 2015
In this fascinating panel interview hosted by The Milken Institute, Auris Health CEO, Dr. Fred Moll, spoke about robotics in healthcare and Auris’s mission to transform medical intervention. According to Moll, the health of the healthcare system was creating a title wave of need for medical intervention. Moll saw this as both a problem and a bigger opportunity.Continue Reading
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.